Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Core Insights - Reviva Pharmaceuticals Holdings, Inc. announced topline data from the long-term open label extension of the Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia, to be presented at the 2025 Congress of the Schizophrenia International Research Society [1][2] Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing next-generation therapeutics for unmet medical needs, particularly in central nervous system (CNS), inflammatory, and cardiometabolic diseases [3] - The company's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - Reviva has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [3]